Canakinumab in a case of adult onset still's disease: EFFICACY only on systemic manifestations

Joint Bone Spine

Volumn 81, Issue 4, 2014, Pages 376-377

  Lo Gullo, Alberto ^a   Caruso, Andrea ^b   Pipitone, Nicolò ^b   Macchioni, Pierluigi ^b   Pazzola, Giulia ^b   Salvarani, Carlo ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Adult onset still disease; Canakinumab; IL 1 blockade; Ultrasonography

Indexed keywords

CANAKINUMAB; CYCLOSPORIN A; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; METHYLPREDNISOLONE; TOCILIZUMAB;

ABDOMINAL PAIN; ADULT; ADULT ONSET STILL DISEASE; ANKLE ARTHRITIS; ANTIBIOTIC THERAPY; ARTHRALGIA; AUTOINFLAMMATORY DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LETTER; PHYSICAL EXAMINATION; PLEURA EFFUSION; RASH; SORE THROAT; SPLENOMEGALY;

ADULT-ONSET STILL DISEASE; CANAKINUMAB; IL-1Β BLOCKADE; ULTRASONOGRAPHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INTERLEUKIN-1BETA; STILL'S DISEASE, ADULT-ONSET;

EID: 84904090065     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.12.011     Document Type: Letter

References (9)

1. Kontzias A., Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 2008, 68:319-337.
2. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
3. Chen D.Y., Lan J.L., Lin F.J., et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004, 31:2189-2198.
4. Dhimolea E. Canakinumab. MAbs 2010, 2:3-13.
5. Yamaguchi M., Ohta A., Tsunematsu T., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
6. Naredo E., Bonilla G., Gamero F., et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005, 64:375-381.
7. Kontzias A., Efthimiou P. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum 2012, 42:201-205.
8. Banse C., Vittecoq O., Benhamou Y., et al. Reactive macrophages activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 2013, 80:653-655.
9. Giampietro C., Ridene M., Lequerre T., et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 2013, 65:822-826.